At ResMed, we’re committed to helping patients with sleep and respiratory disorders. That’s why we support and actively engage in research initiatives on clinical areas related to sleep-disordered breathing.
We’re currently supporting trials that investigate U-Sleep technology, which aims to improve patient compliance with positive airway pressure (PAP) therapy. This trial can also determine whether U-Sleep technology is cost effective. 140 subjects have been enrolled into this trial, with results to be published in late 2014.
With the Orcades trial, we’re evaluating the long-term efficacy of customised Mandibular Repositioning Devices (CadCam, Narval CCTM), over a period of 5 years. Narval CC is often used as an alternative treatment for Obstructive Sleep Apnoea, especially in patients noncompliant with continuous positive airway pressure (CPAP) therapy.
The study has shown the rate of treatment success (defined as a ≥50% decrease in AHI) to be 84%, irrespective of OSA severity or previous CPAP, while AHI was <10/h in 63.4% of patients. 360 patients were enrolled in the study.
ResMed Science Centre
The ResMed Science Centre is a global virtual centre comprised of physicians and research experts from around the globe. The ResMed Science centre is dedicated to undertaking high quality research.
ResMed has a long-standing commitment to clinical excellence, nurtured through our strong partnership with the global clinical community, government and other healthcare organisations, and key opinion leaders. With their help, ResMed supports and actively engages in furthering the growth of knowledge in sleep-disordered breathing and each of the five associated areas of clinical focus.
Obstructive Sleep Apnoea (OSA), one of the most common forms of SDB, has significant links with many of these conditions. SDB treatment has beneficial effects in terms of reducing general healthcare costs and improving patient health.
Our commitment to Research and Development (R&D) makes a difference. ResMed dedicates approximately 7% of annual revenues to R&D.
To learn more about ResMed’s research initiatives in each of these areas, visit our dedicated page.
To receive monthly literature reviews of the latest key clinical literature in SDB and associated conditions, register by email at ScienceCenter@resmed.com.
You can also read or download ResMedica, ResMed’s clinical newsletter here.
The ResMed Foundation
The ResMed Foundation, established in 2002, provides funding of around 1 million US dollars per year to support clinical research related to sleep-disordered breathing. The ResMed foundation aims to increase physician and public awareness of sleep and breathing. For more information on the ResMed Foundation and funding, visit our dedicated website.